Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

48.56 +1.47 (+3.12%)

Streaming Delayed Price Updated: 12:07 PM EDT, Mar 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

35 36 Next >

Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock ↗

December 18, 2022

Both stocks are heading for double-digit gains this year.

Via The Motley Fool

3 Beaten-Down Stocks That Could Explode Higher in 2023 ↗

December 17, 2022

These stocks could have significant upside opportunities ahead.

Via The Motley Fool

7 Stocks to Add to Your 10x Watchlist ↗

December 16, 2022

It’s always a good time to look for stocks with exceptional growth potential. Here are seven 10x stocks for your watchlist.

Via InvestorPlace

3 Growth Stocks With More Potential Than Any Cryptocurrency ↗

December 15, 2022

If the crypto meltdown has you discouraged, don't give up on stocks.

Via The Motley Fool

3 Red-Hot Stocks That Could Continue to Beat the Market ↗

December 11, 2022

The success these stocks achieved in 2022 could be just the beginning.

Via The Motley Fool

What 5 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

November 23, 2022

Via Benzinga

Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition

December 10, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Want to Be Ready For a New Bull Market? Do These 3 Things Soon ↗

December 09, 2022

It's easier to make money in bull markets when you've done the prep work beforehand.

Via The Motley Fool

2 Growth Stocks That Could Help Set You Up for Life ↗

December 09, 2022

Many growth stocks are down, but they're not all out.

Via The Motley Fool

5 Best Bargain Stocks to Buy Before 2023 ↗

December 09, 2022

It's time to hit the best sale in town, and that involves many top stocks.

Via The Motley Fool

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

December 08, 2022

The three companies are changing the pharmaceutical industry.

Via The Motley Fool

Is CRISPR Therapeutics a Buy? ↗

December 08, 2022

A strong cash position could offset some of the near-term risks that come with owning the biotech.

Via The Motley Fool

Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy ↗

December 08, 2022

-Clinical Data Due Next Week at ASH-

Via Benzinga

2 Unstoppable Growth Stocks to Buy in 2022 and Beyond ↗

December 08, 2022

These biotech players beat the bear market this year.

Via The Motley Fool

3 Fierce Stocks That Are Screaming Buys in December ↗

December 07, 2022

Here are three winners in the making.

Via The Motley Fool

Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗

December 06, 2022

The company has already made plenty of investors happy.

Via The Motley Fool

Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023 ↗

December 06, 2022

These top players are ripe for recovery -- and long-term growth.

Via The Motley Fool

3 Growth Stocks That Are Too Cheap to Ignore ↗

December 01, 2022

Overlooking these stocks in the current market could be a mistake.

Via The Motley Fool

Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing ↗

November 28, 2022

Here's how Ark Invest's top holdings have performed in 2022.

Via Investor's Business Daily

2 Stocks Near 52-Week Highs That Could Climb Higher ↗

November 28, 2022

This pair of stocks are bucking the trend and they could climb even higher.

Via The Motley Fool

Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead ↗

November 25, 2022

The ARK Invest founder might regret trimming her position in this biotech stock.

Via The Motley Fool

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

Where Will Editas Medicine Be in 1 Year? ↗

November 20, 2022

The company could continue lagging the market for a while.

Via The Motley Fool

2 Growth Stocks That Could Double in 2023 ↗

November 17, 2022

Both are lagging the market this year.

Via The Motley Fool

Crispr Therapeutics Stock: Bull vs. Bear ↗

November 15, 2022

Crispr shares have fallen about 20% so far this year.

Via The Motley Fool

5 Top Stocks to Buy Before 2023 ↗

November 15, 2022

These stocks have what it takes to win over time.

Via The Motley Fool

Vertex Pharmaceuticals: Buy at the High? ↗

November 14, 2022

Vertex is submitting a potential blockbuster to regulators this month.

Via The Motley Fool

Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait a Decade ↗

November 12, 2022

These top stocks could be wise additions to a well-rounded investment portfolio.

Via The Motley Fool

3 Top Healthcare Stocks Defying the Bear Market ↗

November 10, 2022

These healthcare companies haven't been slowed by macroeconomic conditions.

Via The Motley Fool

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today ↗

November 09, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 15.41% on an annualized basis producing an average annual return of 23.37%. Currently, CRISPR Therapeutics has a...

Via Benzinga

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.